3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
BeOne Medicines's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 498.32%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BeOne Medicines's 3-Year ROIIC % or its related term are showing as below:
ONC's 3-Year ROIIC % is ranked better than 90.83% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs ONC: 498.32
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BeOne Medicines 3-Year ROIIC % Related Terms
BeOne Medicines 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs MRNA, RPRX, ROIV: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, BeOne Medicines's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
BeOne Medicines (ONC) has a 3-Year ROIIC % of 498.32 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #121 out of 1320 companies in the Biotechnology industry, placing it in the top 9.2%.
Is BeOne Medicines' 3-Year ROIIC % too high?
BeOne Medicines' current 3-Year ROIIC % is 498.32. Based on the distribution chart, BeOne Medicines ranks #121 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' 3-Year ROIIC % compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #121 out of 1320 companies for 3-Year ROIIC %. This places BeOne Medicines in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current 3-Year ROIIC % is 498.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.92, compared to a current price of $302.83 — trading 17.7% below its estimated fair value. The current 3-Year ROIIC % is 498.32. BeOne Medicines' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For BeOne Medicines (ONC), the current 3-Year ROIIC % is 498.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $302.83 is trading 17.7% below its estimated GF Value™ of $367.92.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
3-Year ROIIC %: 498.32
GF Value™: $367.92 vs. price of $302.83 (17.7% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score
Get the complete analysis for ONC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
